Literature DB >> 9648714

Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product.

E R Stiehm1, A M Casillas, J Z Finkelstein, K T Gallagher, P M Groncy, R H Kobayashi, J M Oleske, R L Roberts, E T Sandberg, M E Wakim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9648714     DOI： 10.1016/S0091-6749(98)70314-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  12 in total

1.  A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.

Authors:  Melvin Berger
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

2.  Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.

Authors:  Ann Gardulf; Uwe Nicolay; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz Costa Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Jaune Pons; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Clin Immunol       Date:  2006-04-26       Impact factor: 8.317

3.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 5.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

Review 6.  Clinical immunology in practice, new opportunities.

Authors:  Mark R Stein
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

7.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

8.  Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.

Authors:  Akhilesh Chouksey; Kimberly Duff; Nancy Wasserbauer; Melvin Berger
Journal:  Allergy Asthma Clin Immunol       Date:  2005-09-15       Impact factor: 3.406

9.  Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Authors:  John B Hagan; Mary B Fasano; Sheldon Spector; Richard L Wasserman; Isaac Melamed; Mikhail A Rojavin; Othmar Zenker; Jordan S Orange
Journal:  J Clin Immunol       Date:  2010-05-08       Impact factor: 8.317

Review 10.  Immunoglobulin replacement therapy in children.

Authors:  Maria Garcia-Lloret; Sean McGhee; Talal A Chatila
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.